Quick Answer
ADC Therapeutics SA reported Cash And Cash Equivalents At Carrying Value of $261.34 million for the year ending 2025.
- ADC Therapeutics SA showed an increase of +4.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $234.29 million | Q2 2024: $300.12 million | Q3 2024: $274.27 million | Q1 2025: $194.70 million | Q2 2025: $264.56 million | Q3 2025: $234.74 million.
- Over the full 4 years of available data (2022 to 2025), ADC Therapeutics SA's Cash And Cash Equivalents At Carrying Value has declined by 19.9%.
- Historical annual values: Fiscal year 2025: $261.34 million | Fiscal year 2024: $250.87 million | Fiscal year 2023: $278.60 million | Fiscal year 2022: $326.44 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: